12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TRV027: Phase IIa data

A double-blind, placebo-controlled, international Phase IIa trial in 33 catheterized patients with stable New York Heart Association (NYHA) class III/IV heart failure with reduced ejection fraction showed that IV TRV027 "rapidly and reversibly" decreased both blood pressure and PCWP, which...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >